版本:
中国

BRIEF-Synthetic Biologics receives FDA breakthrough therapy designation for SYN-004

May 11 Synthetic Biologics Inc-

* SYN-004 (ribaxamase) receives breakthrough therapy designation from U.S. Food and Drug Administration for prevention of clostridium difficile infection

* Synthetic Biologics-anticipate requesting type-b multidisciplinary meeting with agency for discussion on development plan, pathway to licensure for ribaxamase Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐